|
|||||||||||||||||||||||||||||||||||
PipelineGenetic Immunity's pipeline products are based on the experience and know-how gained during the development of DermaVir Patch, a topically administered HIV Nanomedicine candidate designed to amplify the immune system to specifically kill HIV-infected cells.
Immune Therapy for Dust Mite Allergy Genetic Immunity is leveraging its nanomedicine immune amplification platform technology to develop DermAll Patch. A Nanomedicine nanoparticle is formulated with a plasmid DNA encoding a special allergen. Repeated administration of the DermAll Patch treatment has the potential to control allergy similar to DermaVir Patch treatment for HIV/AIDS. The DermAll Patch development program is a collaboration with University Szeged, which is currently evaluating the product candidate in a mouse model. Immune Therapy for Chlamydia Infection Genetic Immunity is leveraging its nanomedicine immune amplification platform technology to develop ChlamyDerm Patch against Chlamydia Infection. A Nanomedicine nanoparticle is formulated with a plasmid DNA encoding the special antigens of Chlamydia pneumoniae, an intracellular bacterium. The ChlamyDerm Patch development program is a collaboration with University Semmelweis, which is currently evaluating the product candidate in a mouse model. Immune Therapies for Cancer Genetic Immunity's immune therapy technology platform is potentially applicable for the development of new cancer theraphy utilising plasmid DNA encoding tumor-specific antigens. Human papilomavirus is one of the major causes of cervical cancer. Genetic Immunity designed a plasmid DNA expressing the appropriate HPV sequences. The HPV nanomedicine candidate - HuPaDerm - is expected to induce HPV-specific precursor T-cells that can proliferate and kill tumor cells harboring the virus.
|
|
||||||||||||||||||||||||||||||||||
| Home | About Us | Technology | Products | Pipeline | Clinical Trials | Newsroom | Investors | Contacts | Site Map | Last Update: May 14, 2009 |